Compare PAVM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVM | PPBT |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | Israel |
| Employees | 107 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 45.3M |
| IPO Year | N/A | 2014 |
| Metric | PAVM | PPBT |
|---|---|---|
| Price | $8.53 | $3.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $510.00 | $30.00 |
| AVG Volume (30 Days) | 13.6K | ★ 33.3K |
| Earning Date | 05-14-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.41 |
| 52 Week High | $28.44 | $5.18 |
| Indicator | PAVM | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 65.72 |
| Support Level | $8.43 | $3.65 |
| Resistance Level | $9.26 | $5.18 |
| Average True Range (ATR) | 0.54 | 0.36 |
| MACD | -0.25 | -0.12 |
| Stochastic Oscillator | 10.40 | 39.44 |
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.